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lent users was only significant between lovastatin and
pravastatin. 
 
CONCLUSION:
 
 Pravastatin is associated with
less healthcare resource utilization in new users, possibly
due to lack of interaction effects. In prevalent users, the
differences were minimized, possibly due to adjustments
in drug and dosage regimens.
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Much of research on the costs of diabetes mellitus has fo-
cused on long-term complications. There are limited data
on the factors associated with acute diabetes-related
events. OBJECTIVE: The goal of this study was to iden-
tify predictors of acute diabetes complications in a man-
aged-care setting. METHODS: Using a retrospective co-
hort design and a database that linked medical claims
and clinical laboratory data, adult members of a New
England health plan with a diagnosis of diabetes mellitus
between January 1, 1994 through June 30, 1998 were
identified. Inpatient admissions with diagnoses consistent
with acute (“short-term”) diabetes complications (repre-
sented primarily by hyperglycemia, hypoglycemia, and
selected infections) were then evaluated, and expressed
on a 3-year basis. Stratified and multivariate logistic re-
gression analyses were employed to determine the influ-
ence of key factors, such as age, gender, mean glycosy-
lated hemoglobin (HbA1c) value, whether the patient
had a diagnosis of cancer, and whether the patient had
long-term diabetes complications, on the risk of inpatient
admission. RESULTS: Of 2,394 patients with diabetes
mellitus, approximately 11% (269) had at least one inpa-
tient stay for an acute complication over 3 years. The risk
of inpatient treatment for short-term complications was
found to increase 22% (odds ratio 1.22, P  0.01) for
every one point increase in HbA1c. In addition, advanc-
ing age (odds ratios of 1.63 and 2.56 for patients 60 to
69 years and 70 years relative to under 50 years, re-
spectively; both P  0.05), long-term complications
(odds ratio 9.39, P  0.01), and cancer (odds ratio 3.13,
P  0.01) all were associated with increasing risk. CON-
CLUSIONS: In clinical practice, we found that poorer
glycemic control, age, and comorbidity are independent
risk factors for acute diabetes complications. Further re-
search is needed to determine whether better risk-factor
management (e.g., control of HbA1c) can reduce the rate
of acute diabetes complications.
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In 1996 the FDA approved donepezil for treatment of
Alzheimer’s patients with symptoms of memory and cog-
nitive loss. A recent study projected that the cost of done-
pezil could be offset by reduced utilization over a two-
year period. OBJECTIVES: The purpose of this study
was to measure use of donepezil among Veteran’s Health
Administration (VHA) patients during FY’98 and the im-
pact on cost. METHODS: Patients diagnosed with
Alzheimer’s disease in five VHA medical centers were
identified and costs for inpatient and outpatient care
were calculated based on Medicare reimbursement rates.
Extended care costs were calculated at $236 per day
(VHA national per diem). Prescription costs were calcu-
lated using VHA Pharmacy Benefit Management prices.
Patients with medical contraindications, those who died
during the study period, and those admitted to an ex-
tended care facility prior to the beginning of the fiscal
year, were excluded from the analysis. Regression analy-
sis was used to measure the association between done-
pezil use and cost while controlling for severity, comor-
bidity, previous hospitalizations, and site. RESULTS:
Donepezil was used by 11% (167) of patients with no
contraindications (N  1484). The regression analyses
indicated donepezil users had higher pharmaceutical
($800, P  0.0001) and outpatient costs ($801, P 
0.006), but lower inpatient (acute plus extended care)
costs ($1542, P  0.10). There was no substantial dif-
ference in total cost ($58, P  0.95). CONCLUSION:
The results support the hypothesis that higher pharma-
ceutical and outpatients costs related to donepezil use are
offset by lower inpatient costs. The extent of the offset
may be greater for the VHA (due to substantial discounts
with drug manufacturers), than would be found in other
health care systems.
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OBJECTIVE: The objective of this study was to compare
survival and costs before and after the availability of
52 Abstracts
HAART as a treatment regimen for HIV-infected individ-
uals at a Veterans Affairs Medical Center. STUDY DE-
SIGN: This was a retrospective database study covering
five US government fiscal years (1994 through 1998).
During that time frame, protease inhibitors were intro-
duced, allowing the use of potent combination drug ther-
apy known as highly-active antiretroviral therapy
(HAART). METHODS: Survival methods were used to
analyze differences in total costs of care and survival be-
tween two cohorts treated when HAART was not avail-
able and when HAART was available. Survival was mea-
sured in days. Health care costs were available for
hospitalizations, clinic visits, outpatient medications, and
laboratory procedures. A sensitivity analysis was per-
formed to determine the impact of estimates for the costs
of clinic visits of varying lengths. RESULTS: Statistically
significant improvements in survival and reductions in
costs were observed for the time period after HAART be-
came available. Mean survival increased from 589 days
before the availability of HAART to 702 days after
HAART became available (P  0.001). Median annual
costs of care decreased from $29,477 to $16,219 (P 
0.001). CONCLUSIONS: The availability of potent, yet
expensive, antiretroviral medications for the treatment of
HIV-infected individuals at the Denver VAMC has re-
sulted in improved survival and lower overall medical
care costs.
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AN ANALYSIS OF THE IMPACT OF MEDICATION 
NON-ADHERENCE AND TYPE OF MEDICATION 
ON OUTCOME DOMAINS USING THE SCAP 
HEALTH QUESTIONNAIRE
Russo P, Dirani R
The MEDSTAT Group, Inc., Washington, DC, USA
OBJECTIVE: To model the effects of medication non-
adherence and type of medication on health status, func-
tioning, and quality of life outcomes for persons with
schizophrenia enrolled in the US Schizophrenia Care and
Assessment Program (SCAP). METHODS: Data were
obtained from SCAP study participants who completed
the baseline and the 6-month assessments and who were
using antipsychotic medications (n  530). Baseline char-
acteristics and type of medication were used to predict 6-
month outcomes as measured by the SCAP Health Ques-
tionnaire (SCAPHQ). Adherence at baseline and at six
months reflected the 4-week period prior to each assess-
ment. Health status (health score), functioning (social
and daily activity), and quality of life (general life satis-
faction) were modeled using ordinary least squares. RE-
SULTS: No family history, undifferentiated type, private
health insurance, and Medicare only were predictive of
higher health scores. Being married and non-adherence at
six months were predictive of lower health scores. Within
the functioning domain, a college education and better
health were predictors of higher social activities scores
while persons on CHAMPUS exhibited lower scores. Bet-
ter health, undifferentiated type, and summer birth were
predictive of higher life satisfaction. Cohort (recently
hospitalized) and medication non-adherence (at baseline
and at 6 months) exhibited a negative impact on life sat-
isfaction. CONCLUSIONS: These findings suggest that
prior period self-reported adherence may be predictive of
subsequent period outcomes in health status and quality
of life. Medication non-adherence is significantly associ-
ated with lower health status and lower life satisfaction
and exhibits a negative (though non-significant) impact
on functioning outcomes. Education and health status
are important determinants of functioning outcomes.
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Between 7/93 and 6/95, Medicare gradually extended
its maintenance immunosuppression medication (MIM)
coverage from 1 to its current 3 years. OBJECTIVES:
We hypothesized that lower income recipients would
be more non-compliant because of the high cost of
MIMs. We examined whether Medicare’s extension
benefited low-income recipients more. METHODS:
We matched median family income for each patient’s
ZIP code from the 1990 Census with clinical data on
first cadaveric renal transplants from the USRDS-dis-
tributed UNOS registry. We used Kaplan-Meier plots
and Cox Proportional Hazards Models to analyze the
differences in graft survival in the two chronological
cohorts (6,279 and 10,060 recipients before and after
the extended coverage, respectively) and two income
groups (above and below the upper quartile family in-
come of $33,277). RESULTS: When Medicare cov-
ered MIMs for 1 year, the high and lower income
groups had equivalent graft survival at 1 year. By 3
years post-transplant the lower income group had a
4.4% greater graft failure (P  0.001). Among 1 year
survivors, the lower income group eligible for only 1
year MIM coverage had a 5% greater graft failure at
the end of three years post-transplant (P  0.001).
The risk ratios from a multivariate Cox Proportional
Hazards model indicate that Medicare’s extended cov-
erage eliminated the entire differential graft loss asso-
ciated with lower incomes. Even in the next-to-highest
income quartile, the graft loss (RR  1.37, P  0.008)
and the benefits of extended coverage (RR  0.70,
P  0.035) were significant. CONCLUSION: We in-
fer that extended MIM coverage improved compliance
for all but the highest income recipients. This should
